Pharmacodynamics News and Research

RSS
Study identifies urinary biomarker that may help monitor progression of ALS

Study identifies urinary biomarker that may help monitor progression of ALS

University of Liverpool to establish new research centre to accelerate development of novel antibiotics

University of Liverpool to establish new research centre to accelerate development of novel antibiotics

Ardelyx initiates two clinical trials to evaluate new treatment for hyperkalemia

Ardelyx initiates two clinical trials to evaluate new treatment for hyperkalemia

Two research studies on new molecules could potentially treat Alzheimer's disease

Two research studies on new molecules could potentially treat Alzheimer's disease

Combined endocrine and targeted therapy could be effective in treating Asian breast cancer patients

Combined endocrine and targeted therapy could be effective in treating Asian breast cancer patients

Getting drugs to bugs in NTM lung infections: an interview with Dr Jakko van Ingen

Getting drugs to bugs in NTM lung infections: an interview with Dr Jakko van Ingen

FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Tackling healthcare challenges in a changing world: an interview with Professor Jeremy Nicholson

Tackling healthcare challenges in a changing world: an interview with Professor Jeremy Nicholson

Sophisticated technology helps model and simulate optimal dose for pediatric ependymoma patients

Sophisticated technology helps model and simulate optimal dose for pediatric ependymoma patients

Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

BioAgilytix announces acquisition of IPM Biotech

BioAgilytix announces acquisition of IPM Biotech

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus reports net loss of $7.2 million for fourth quarter 2015

Research shows significant step toward improving outcomes, reducing treatment burden for SCD patients

Research shows significant step toward improving outcomes, reducing treatment burden for SCD patients

MIPT researchers patent graphene biosensors that may accelerate development of novel drugs

MIPT researchers patent graphene biosensors that may accelerate development of novel drugs

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Drug interactions in placenta may increase risk of birth defects or stunting fetal growth

Drug interactions in placenta may increase risk of birth defects or stunting fetal growth

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress